Dr. Mayo is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5323 Harry Hines Blvd
Dallas, TX 75390Phone+1 214-645-8600Fax+1 214-645-0596
Education & Training
- University of Texas Southwestern Medical CenterFellowship, Gastroenterology, 1993 - 1996
- University of California (Irvine)Residency, Internal Medicine, 1990 - 1993
- Baylor College of MedicineClass of 1990
Certifications & Licensure
- CA State Medical License 1992 - Present
- TX State Medical License 1992 - 2026
- American Board of Internal Medicine Gastroenterology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
- Fellow (AGAF) American Gastroenterological Association, 2011
Clinical Trials
- Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis Start of enrollment: 2013 Aug 01
Publications & Presentations
PubMed
- 196 citationsTerlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1Thomas D. Boyer, Arun J. Sanyal, Florence Wong, R. Todd Frederick, John R. Lake
Gastroenterology. 2016-06-01 - 62 citationsEpigenetic investigation of variably X chromosome inactivated genes in monozygotic female twins discordant for primary biliary cirrhosis.Michelle M. Mitchell, Ana Lleo, Luca Zammataro, Marlyn J. Mayo, Pietro Invernizzi
Epigenetics. 2011-01-01 - 358 citationsPrimary biliary cirrhosis in monozygotic and dizygotic twins: Genetics, epigenetics, and environment ☆Carlo Selmi, Marlyn J. Mayo, Nancy Bach, Hiromi Ishibashi, Pietro Invernizzi
Gastroenterology. 2004-08-01
Journal Articles
- Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver DiseasesMarlyn (Krampitz) Mayo, MD, Hepatology
Authored Content
- The Liver Meeting's Highlights and LowlightsNovember 2023
Press Mentions
- Pioneering Discussions at IISLD 2024: Advancing Treatment for PBC and Alpha-1 Antitrypsin DeficiencyOctober 11th, 2024
- Study Outlines Risk Factors for Autoimmune Hepatitis After Liver TransplantMay 20th, 2022
- CymaBay Therapeutics to Host Post-AASLD Key Opinion Leader Webinar on Seladelpar for Primary Biliary CholangitisNovember 11th, 2021
- Join now to see all
Grant Support
- Ursodeoxycholic Acid (UDCA) In Primary Biliary CirrhosisNational Center For Research Resources2007
- UDCA Amp;Methotrexate For Primary Biliary CirrhosisNational Center For Research Resources2007
- Treatment Of Metabolic PruritisNational Center For Research Resources2004–2007
- UDCA &Methotrexate For Primary Biliary CirrhosisNational Center For Research Resources2006
- Longitudinal Studies Of Primary Biliary CirrhosisNational Institute Of Diabetes And Digestive And Kidney Diseases2005–2006
- 1treatment Of Cholestatic Pruritus With SertralineNational Institute Of Diabetes And Digestive And Kidney Diseases2003–2004
- Role Of CD40-CD40 Ligand In Primary Biliary CirrhosisNational Institute Of Diabetes And Digestive And Kidney Diseases2000–2003
- Role Of CD40 Ligand In Primary Biliary CirrhosisNational Center For Research Resources1998–2002
Committees
- Member, Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD) 2016 - Present
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: